

March 31, 2022  
SymBio Pharmaceuticals Limited  
Fuminori Yoshida  
Representative Director  
President and Chief Executive Officer  
(Securities Code: 4582)

## Notice of Renewal of Syndicated Loan Agreement

TOKYO, Japan, March 31, 2022 -- SymBio Pharmaceuticals Limited (Headquarters: Tokyo, "SymBio") today announced that SymBio renewed its syndicated loan (commitment line) agreement for which MUFG Bank, Ltd. acts as the arranger and agent(the "Agreement") as follows:

### 1. Purpose of the Agreement

The purpose of the agreement is to establish a stable and flexible financing system in line with business expansion.

### 2. Outline of the Syndicated Loan Agreement

|                                      |  |
|--------------------------------------|--|
| Amount of Syndicated Loan            | JPY 3,150 million  |
| Execution Date                       | March 31, 2022   |
| Form of Contract                     | Commitment line contract   |
| Commitment Period                    | April 5, 2022 - April 4, 2024  |
| Use of Funds                         | Working capital  |
| Repayment Method                     | Lump-sum repayment on repayment date for each loan                             |
| Applicable Interest Rate             | Base interest rate plus spread   |
| Collateral                           | Unsecured  |
| Arranger and Agent                   | MUFG Bank, Ltd.  |
| Participating Financial Institutions | MUFG Bank, Ltd.<br>Sumitomo Mitsui Banking Corporation<br>Resona Bank, Limited |

### 3. Impact on Financial Outlook

SymBio does not expect the information presented herein to have any material impact on its financial outlook for the fiscal year ending December 2022.

Contact

Investor Relations

Tel: +81 (0)3 5472 1125